{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T02:46:37Z","timestamp":1761965197048,"version":"3.37.3"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,9,29]],"date-time":"2020-09-29T00:00:00Z","timestamp":1601337600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,9,29]],"date-time":"2020-09-29T00:00:00Z","timestamp":1601337600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Minimal change disease (MCD) is one of the causes of idiopathic nephrotic syndrome in adults. The pathogenesis of proteinuria in MCD has not been fully understood. Recently, it has been reported that the receptor activator of nuclear factor-kappa B (RANK)\/RANK ligand (RANKL) may contribute to the podocyte biology in kidney diseases. Denosumab is a human anti-RANKL monoclonal antibody used to treat osteoporosis. Here we report a case of MCD after denosumab administration.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Case presentation<\/jats:title>\n<jats:p>A 59-year-old male without any episodes of proteinuria was given denosumab to treat osteoporosis. Two weeks after its administration, he noticed a foamy urine and bilateral pretibial edema. Laboratory tests revealed that he had severe proteinuria (15g\/g Cr), hypoproteinemia (4.0g\/dL), and hypoalbuminemia (1.5g\/dL). Based on the results, he was diagnosed with nephrotic syndrome. The proteinuria selectivity index was 0.05, indicating selective proteinuria. Renal biopsy showed minor glomerular abnormality with less tubulointerstitial damage, and electron microscopy showed extensive foot process effacement, indicating MCD. With all these results, glucocorticoid therapy of 50mg\/day prednisolone was started. After 4weeks of treatment, the urinary protein level remains high (3.1g\/g Cr). Prednisolone therapy was continued, and the levels of proteinuria decreased gradually to the range of partial remission (1.2g\/g Cr) with another 7weeks of prednisolone treatment, but complete remission was not achieved.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusions<\/jats:title>\n<jats:p>This might be a case wherein RANKL inhibition is associated with the pathogenesis of MCD. Further studies will be needed to elucidate the causal relationship of RANK-RANKL signaling to the pathogenesis of MCD.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s12882-020-02066-3","type":"journal-article","created":{"date-parts":[[2020,9,29]],"date-time":"2020-09-29T12:03:11Z","timestamp":1601380991000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["A case of minimal change disease after the administration of anti receptor activator of nuclear factor kappa B ligand (RANKL) monoclonal antibody: a case report"],"prefix":"10.1186","volume":"21","author":[{"given":"Keisuke","family":"Horikoshi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7245-9716","authenticated-orcid":false,"given":"Norihiko","family":"Sakai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoki","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hisayuki","family":"Ogura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koichi","family":"Sato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taro","family":"Miyagawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinji","family":"Kitajima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tadashi","family":"Toyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akinori","family":"Hara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasunori","family":"Iwata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miho","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kengo","family":"Furuichi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Wada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,9,29]]},"reference":[{"key":"2066_CR1","doi-asserted-by":"publisher","first-page":"332","DOI":"10.2215\/CJN.05000516","volume":"12","author":"M Vivarelli","year":"2017","unstructured":"Vivarelli M, Massella L, Ruggiero B, Emma F. Minimal change disease. Clin J Am Soc Nephrol. 2017;12:332\u201345.","journal-title":"Clin J Am Soc Nephrol"},{"key":"2066_CR2","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/S0272-6386(87)80170-1","volume":"10","author":"JS Cameron","year":"1987","unstructured":"Cameron JS. The nephrotic syndrome and its complications. Am J Kidney Dis. 1987;10:157\u201371.","journal-title":"Am J Kidney Dis"},{"key":"2066_CR3","doi-asserted-by":"publisher","first-page":"2101","DOI":"10.2169\/internalmedicine.54.3927","volume":"54","author":"L Zhao","year":"2015","unstructured":"Zhao L, Cheng J, Zhou J, Wu C, Chen J. Enhanced steroid therapy in adult minimal change Nephrotic syndrome: a systematic review and meta-analysis. Intern Med. 2015;54:2101\u20138.","journal-title":"Intern Med"},{"key":"2066_CR4","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1053\/ajkd.2002.31400","volume":"39","author":"M Nakayama","year":"2002","unstructured":"Nakayama M, Katafuchi R, Yanase T, Ikeda K, Tanaka H, Fujimi S. Steroid responsiveness and frequency of relapse in adult-onset minimal change nephrotic syndrome. Am J Kidney Dis. 2002;39:503\u201312.","journal-title":"Am J Kidney Dis"},{"key":"2066_CR5","doi-asserted-by":"publisher","first-page":"3597","DOI":"10.1073\/pnas.95.7.3597","volume":"95","author":"H Yasuda","year":"1998","unstructured":"Yasuda H, Shima N, Nakagawa N, et al. Osteoclast differentiation factor is a ligand for osteoprotegerin\/osteoclastogenesis-inhibitory factor and identical to TRANCE\/RANKL. Proc Natl Acad Sci U S A. 1998;95:3597\u2013602.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2066_CR6","doi-asserted-by":"publisher","first-page":"5342","DOI":"10.1073\/pnas.1013054108","volume":"108","author":"V Duheron","year":"2011","unstructured":"Duheron V, Hess E, Duval M, et al. Receptor activator of NF-kappa B (RANK) stimulates the proliferation of epithelial cells of the epidermo-pilosebaceous unit. Proc Natl Acad Sci U S A. 2011;108:5342\u20137.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2066_CR7","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/S0092-8674(00)00103-3","volume":"103","author":"JE Fata","year":"2000","unstructured":"Fata JE, Kong YY, Li J, et al. The osteoclast differentiation factor osteoprotegerin-ligand is essential for mammary gland development. Cell. 2000;103:41\u201350.","journal-title":"Cell."},{"key":"2066_CR8","doi-asserted-by":"publisher","first-page":"2989","DOI":"10.1073\/pnas.0915148107","volume":"107","author":"M Beleut","year":"2010","unstructured":"Beleut M, Rajaram RD, Caikovski M, et al. Two distinct mechanisms underlie progesterone-induced proliferation in the mammary gland. Proc Natl Acad Sci US. 2010;107:2989\u201394.","journal-title":"Proc Natl Acad Sci US"},{"key":"2066_CR9","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/S8756-3282(99)00214-8","volume":"25","author":"V Kartsogiannis","year":"1999","unstructured":"Kartsogiannis V, Zhou H, Horwood NJ, et al. Localization of RANKL (receptor activator of NF kappa B ligand) mRNA and protein in skeletal and extraskeletal tissues. Bone. 1999;25:525\u201334.","journal-title":"Bone."},{"key":"2066_CR10","doi-asserted-by":"publisher","first-page":"e41331","DOI":"10.1371\/journal.pone.0041331","volume":"7","author":"S Liu","year":"2012","unstructured":"Liu S, Shi W, Xiao H, et al. Receptor activator of NF-kappaB and podocytes: towards a function of a novel receptor-ligand pair in the survival response of podocyte injury. PLoS One. 2012;7:e41331.","journal-title":"PLoS One"},{"key":"2066_CR11","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1359\/JBMR.040305","volume":"19","author":"PJ Bekker","year":"2004","unstructured":"Bekker PJ, Holloway DL, Rasmussen AS, et al. A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J Bone Miner Res. 2004;19:1059\u201366.","journal-title":"J Bone Miner Res"},{"key":"2066_CR12","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.molmed.2005.11.007","volume":"12","author":"T Wada","year":"2006","unstructured":"Wada T, Nakashima T, Hiroshi N, Penninger JM. RANKL-RANK signaling in osteoclastogenesis and bone disease. Trends Mol Med. 2006;12:17\u201325.","journal-title":"Trends Mol Med"},{"issue":"Suppl 1","key":"2066_CR13","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1186\/ar2165","volume":"9","author":"BF Boyce","year":"2007","unstructured":"Boyce BF, Xing L. Biology of RANK, RANKL, and osteoprotegerin. Arthritis Res Ther. 2007;9(Suppl 1):S1.","journal-title":"Arthritis Res Ther"},{"key":"2066_CR14","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.3892\/etm.2016.3184","volume":"11","author":"YX Zhou","year":"2016","unstructured":"Zhou YX, Shi LX, Yang H, et al. Effects of a GSK- 3\u03b2 inhibitor on the renal expression levels of RANK, RANKL and NF- \ud705B in a rat model of diabetic nephropathy. Exp Ther Med. 2016;11:2495\u2013502.","journal-title":"Exp Ther Med"},{"key":"2066_CR15","doi-asserted-by":"publisher","unstructured":"Chen XW, Du XY, Wang YX, et al. Irbesartan ameliorates diabetic nephropathy by suppressing the RANKL-RANK-NF- \ud705B pathway in type 2 diabetic db\/db mice. Mediat Inflamm. 2016. https:\/\/doi.org\/10.1155\/2016\/1405924.","DOI":"10.1155\/2016\/1405924"},{"key":"2066_CR16","doi-asserted-by":"publisher","first-page":"e0197984","DOI":"10.1371\/journal.pone.0197984","volume":"13","author":"Q Chen","year":"2018","unstructured":"Chen Q, Hu C, Liu Y, et al. Pharmacokinetics, pharmacodynamics, safety, and tolerability of single-dose denosumab in healthy Chinese volunteers: a randomized, single-blind, placebo-controlled study. PLoS One. 2018;13:e0197984.","journal-title":"PLoS One"},{"key":"2066_CR17","unstructured":"Prolia (denosumab) injection [prescribing information]. Amgen Inc, Thousand Oaks. 2015. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/125320s174lbl.pdf. Accessed 25 Jan 2016."},{"key":"2066_CR18","unstructured":"Xgeva (denosumab) injection [prescribing information]. Amgen Inc, Thousand Oaks. 2015. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/125320s168lbl.pdf. Accessed 25 Jan 2016."}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-020-02066-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12882-020-02066-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-020-02066-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,29]],"date-time":"2021-09-29T00:09:04Z","timestamp":1632874144000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/s12882-020-02066-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,29]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["2066"],"URL":"https:\/\/doi.org\/10.1186\/s12882-020-02066-3","relation":{},"ISSN":["1471-2369"],"issn-type":[{"type":"electronic","value":"1471-2369"}],"subject":[],"published":{"date-parts":[[2020,9,29]]},"assertion":[{"value":"23 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Written informed consent was obtained from the patient of this case report.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient for publication of case report and any accompanying images. A copy of the consent form is available for review and can be provided on request.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"416"}}